Use of non-opiates for the potentation of opiates
A non-opioid analgesic is used for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic.
1 . A method for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic wherein said method comprises administering to the patient a non-opioid analgesic.
2 . The method according to claim 1 , wherein the pain is chronic benign pain.
3 . The method according to claim 2 , wherein the pain is related to a musculoskeletal, visceral or headache condition.
4 . The method according to claim 3 , wherein the condition is osteoarthritis, rheumatoid arthritis, chronic back pain, chronic pancreatitis or chronic migraine.
5 . The method according to claim 1 , wherein the pain is breakthrough pain in cancer.
6 . The method according to claim 5 , wherein the cancer breakthough pain is primarily neuropathic.
7 . The method according to claim 1 , wherein the non-opioid analgesic is a potentiatior of the opioid analgesic.
8 . The method according to claim 1 , wherein the non-opioid analgesic is selected from antagonists of NMDA, CCK, substance P or Neurokinin, compounds that cause uptake blockade, agonists of alpha 2 or beta 2 adrenoceptors, and COX inhibitors.
9 . The method according to claim 1 , wherein the non-opioid analgesic is selected from clenbuterol, proglumide, devazepide, ifenprodil, nefopam, tramadol, duloxetine and venlafaxine.
10 . The method, according to claim 1 , where the administration is done via a route that avoids first-pass metabolism.
11 . The method according to claim 10 , wherein the route is intranasal.
12 . The method according to claim 10 , wherein the route is sublingual.
13 . The method according to claim 10 , wherein the route is pulmonary.
14 . A product comprising an opioid analgesic and a non-opioid analgesic, as a combined preparation for simultaneous, separate or sequential use in the treatment of chronic pain including intermittent or episodic pain.
15 . The product according to claim 14 , wherein the non-opioid analgesic is a potentiatior of the opioid analgesic.
16 . The product according to claim 14 , wherein the non-opioid analgesis is selected from antagonists of NMDA, CCK, substance P or Neurokinin, compounds that cause uptake blockade, agonists of alpha 2 or beta 2 adrenoceptors, and COX inhibitors.
17 . The product according to claim 14 , wherein the non-opioid analgesic is selected from clenbuterol, proglumide, devazepide, ifenprodil, nefopam, tramadol, duloxetine and venalfaxine.